The Importance of Sphingomyelin Phosphodiesterase Acid-Like 3b (SMPDL-3b) Levels in Kidney Biopsy Specimens of Children With Nephrotic Syndrome.

IF 0.7 4区医学 Q4 PATHOLOGY Fetal and Pediatric Pathology Pub Date : 2023-12-01 Epub Date: 2023-11-22 DOI:10.1080/15513815.2023.2267683

Muhammet Kaya, İlknur Girişgen, Nagihan Yalçın, Tülay Becerir, Hande Şenol, Gülsün Gülten, Selcuk Yüksel

{"title":"The Importance of Sphingomyelin Phosphodiesterase Acid-Like 3b (SMPDL-3b) Levels in Kidney Biopsy Specimens of Children With Nephrotic Syndrome.","authors":"Muhammet Kaya, İlknur Girişgen, Nagihan Yalçın, Tülay Becerir, Hande Şenol, Gülsün Gülten, Selcuk Yüksel","doi":"10.1080/15513815.2023.2267683","DOIUrl":null,"url":null,"abstract":"Objective: It remains unclear whether the low amount of SMPDL-3b required for rituximab binding is the cause of treatment resistance in patients with treatment-resistant nephrotic syndrome with advanced podocyte injury. Given the limited number of studies on the relationship between rituximab and SMPDL-3b, this study was conducted to assess whether SMPDL-3b levels in pretreatment renal biopsy specimens can be used to predict the clinical effectiveness of immunosuppressive drugs, especially rituximab, in children with nephrotic syndrome.Methods: Kidney biopsy specimens from 44 patients diagnosed with idiopatic nephrotic syndrome were analyzed using immunohistochemical staining with an anti-SMPDL-3b antibody and real-time polymerase chain reaction (PCR) for SMPDL-3b mRNA expression.Results: We showed that SMPDL-3b mRNA expression and anti-SMPDL-3b antibody staining did not differ significantly between the patient groups with different responses to immunosuppressive therapies.Conclusion: Our results suggest that SMPDL-3b may actually be an indicator of disease progression rather than a marker for predicting response to a particular immunosuppressive agent.","PeriodicalId":50452,"journal":{"name":"Fetal and Pediatric Pathology","volume":" ","pages":"936-949"},"PeriodicalIF":0.7000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fetal and Pediatric Pathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/15513815.2023.2267683","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/22 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: It remains unclear whether the low amount of SMPDL-3b required for rituximab binding is the cause of treatment resistance in patients with treatment-resistant nephrotic syndrome with advanced podocyte injury. Given the limited number of studies on the relationship between rituximab and SMPDL-3b, this study was conducted to assess whether SMPDL-3b levels in pretreatment renal biopsy specimens can be used to predict the clinical effectiveness of immunosuppressive drugs, especially rituximab, in children with nephrotic syndrome.

Methods: Kidney biopsy specimens from 44 patients diagnosed with idiopatic nephrotic syndrome were analyzed using immunohistochemical staining with an anti-SMPDL-3b antibody and real-time polymerase chain reaction (PCR) for SMPDL-3b mRNA expression.

Results: We showed that SMPDL-3b mRNA expression and anti-SMPDL-3b antibody staining did not differ significantly between the patient groups with different responses to immunosuppressive therapies.

Conclusion: Our results suggest that SMPDL-3b may actually be an indicator of disease progression rather than a marker for predicting response to a particular immunosuppressive agent.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

鞘氨醇磷酸二酯酶类3b（SMPDL-3b）水平在肾病综合征儿童肾脏活检标本中的重要性。

目的：目前尚不清楚利妥昔单抗结合所需的低量SMPDL-3b是否是晚期足细胞损伤的难治性肾病综合征患者治疗耐药性的原因。鉴于关于利妥昔单抗和SMPDL-3b之间关系的研究数量有限，本研究旨在评估预处理肾活检标本中SMPDL-3b水平是否可用于预测免疫抑制药物，尤其是利妥昔mab对肾病综合征儿童的临床疗效。方法：采用抗SMPDL-3b抗体免疫组织化学染色和实时聚合酶链反应（PCR）检测SMPDL-3bmRNA表达，对44例诊断为特发性肾病综合征的患者的肾活检标本进行分析。结果：我们发现，在对免疫抑制治疗有不同反应的患者组之间，SMPDL-3b mRNA表达和抗SMPDL-3b抗体染色没有显著差异。结论：我们的研究结果表明，SMPDL-3b实际上可能是疾病进展的指标，而不是预测对特定免疫抑制剂反应的标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Fetal and Pediatric Pathology 医学-病理学

CiteScore

3.00

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Fetal and Pediatric Pathology is an established bimonthly international journal that publishes data on diseases of the developing embryo, newborns, children, and adolescents. The journal publishes original and review articles and reportable case reports. The expanded scope of the journal encompasses molecular basis of genetic disorders; molecular basis of diseases that lead to implantation failures; molecular basis of abnormal placentation; placentology and molecular basis of habitual abortion; intrauterine development and molecular basis of embryonic death; pathogenisis and etiologic factors involved in sudden infant death syndrome; the underlying molecular basis, and pathogenesis of diseases that lead to morbidity and mortality in newborns; prenatal, perinatal, and pediatric diseases and molecular basis of diseases of childhood including solid tumors and tumors of the hematopoietic system; and experimental and molecular pathology.